PureTech Health plc (PTCHF) Stock Price & Analysis
PureTech Health plc (PTCHF) — price $1.66 (0.00%), as of the Nov 19, 2026 trading session; market cap $406M.
Educational signal · not a buy or sell recommendation · How to read this
PureTech Health plc · PTCHF
PureTech Health plc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics in the United States. It targets a diverse range of challenging medical conditions, leveraging a robust pipeline and strategic collaborations with major pharmaceutical firms.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.66 | |
| Change on the day | 0.00% | |
| 52-week range | $1.45 – $1.92 | |
| Market capitalisation | $406M | — |
| Price / earnings (trailing) | 155.67 | |
| Shares traded on the day | 8.8K |
Price & events
Other perspectives
Council score for PureTech Health (PTCHF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 1, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 1, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is PureTech Health (PTCHF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. PureTech Health plc (PTCHF) is the company analyzed here. It employs 80 people and is led by Robert William Henry Lyne. In Q2 FY2026 it reported revenue of $4M and net income of $66M. The market values it at $406M.
What do the latest results show for PureTech Health (PTCHF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $4M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $4M | $66M | $0.27 (diluted) |
| Q4 FY2025 | $3M | -$66M | -$0.28 (diluted) |
| Q2 FY2025 | $2M | -$45M | -$0.19 (diluted) |
| Q4 FY2024 | $4M | $95M | $0.35 (diluted) |
What are the financial strengths and risks for PureTech Health (PTCHF)?
Short answer · as of
The distress and quality screens read Altman Z 1.07 · Piotroski F 4. Trailing ratios: ROE 0.1% · ROA 0.1% · current ratio 4.60 · earnings yield 0.1% · free-cash-flow yield -21.3%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PTCHF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PTCHF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
PureTech Health Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the PTCHF research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is PTCHF a good stock to buy?
Stock Expert AI does not rate PTCHF buy, sell or hold. PureTech Health plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PTCHF stock price today?
The last price recorded for PureTech Health plc (PTCHF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does PureTech Health plc manage the risks associated with its clinical-stage pipeline?
PureTech Health plc manages clinical-stage pipeline risks through several strategies. Firstly, it maintains a diverse pipeline across multiple therapeutic areas and utilizes various technology platforms, reducing over-reliance on a single drug candidate. This diversification helps mitigate the impact of any single trial failure.
What are the key factors to evaluate for PTCHF?
Evaluate PTCHF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. These opportunities are ongoing and can materialize at various stages of drug development. Not financial advice.
How frequently does PTCHF data refresh on this page?
PTCHF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PTCHF's recent stock price performance?
PureTech Health plc (PTCHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse clinical-stage pipeline targeting a wide array of challenging medical conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PTCHF overvalued or undervalued right now?
The trailing P/E of PureTech Health plc (PTCHF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PTCHF before investing?
Before investing in PureTech Health plc (PTCHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com